Skip to main content
Be The Investor
S&P 500
7,623.52+0.57%
Nasdaq Composite
25,604.03+0.66%
Dow Jones
52,340.31+1.10%
Russell 2000
2,840.80+1.03%
VIX
VIX
18.92-2.57%
Bitcoin
77,315.78-1.18%
Ethereum
2,266.11-0.29%
Solana
93.24-1.28%
Gold
3,978.10+2.03%
Silver
51.01+3.51%
Copper
6.571+1.37%
WTI Crude Oil
96.48-7.34%
US 10-Year Treasury Yield
4.881-0.97%
Home›Stocks›BDX
OverviewChartNewsFinancialsBusiness ModelCompetitorsStatisticsAnalysisEarningsValuationHoldersOptionsInsidersForecastCompareFAQ

Becton, Dickinson and Company

BDX
NYSEUnited States flagUSReal-Time Price
$199.32USD
+1.44 (+0.73%)Today
BTI Score

BASIC required or higher

View pricing
BTI Fair Market Cap
$27.65B
+96.35% vs fair
Healthcare & Pharma
Hold

Becton, Dickinson and Company (BDX) Valuation

Is Becton, Dickinson and Company (BDX) overvalued or undervalued? BTI's fair-value estimate, DCF model and valuation multiples show the premium or discount to intrinsic worth.

Valuation Snapshot

P/E (TTM)
Trailing Price-to-Earnings
60.04
Forward P/E
Next 12 months estimate
—
PEG Ratio
P/E to Growth ratio
—
Price / Sales
Market cap vs. revenue
—
Price / Book
Market cap vs. book value
—
EV / EBITDA
Enterprise value multiple
—
Earnings Yield
Inverse of P/E
1.67%
Revenue Growth
Year-over-year
—

Valuation Risk

Becton, Dickinson and Company trades at a premium P/E of 60.04x, indicating that the market is pricing in significant future growth. High-multiple stocks can be vulnerable to earnings disappointments or rising interest rates.

Run Full Valuation Model
DCF, multiples, scenario analysis and AI fair value for BDX